|
1
|
Wijdicks EF and Klein CJ: Guillain-barré
syndrome. Mayo Clin Proc. 92:467–479. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Barbee MS, Ogunniyi A, Horvat TZ and Dang
TO: Current status and future directions of the immune checkpoint
inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Ann Pharmacother. 49:907–937. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med.
372:2521–2532. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Seiwert TY, Burtness B, Mehra R, Weiss J,
Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et
al: Safety and clinical activity of pembrolizumab for treatment of
recurrent or metastatic squamous cell carcinoma of the head and
neck (KEYNOTE-012): An open-label, multicentre, phase 1B trial.
Lancet Oncol. 17:956–965. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: Pembrolizumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Haanen JBAG, Carbonnel F, Robert C, Kerr
KM, Peters S, Larkin J and Jordan K: ESMO Guidelines Committee:
Management of toxicities from immunotherapy: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28
(suppl 4):iv119–iv142. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Brahmer JR, Lacchetti C, Schneider BJ,
Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner
JM, Ginex P, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: American
society of clinical oncology clinical practice guideline. J Clin
Oncol. 36:1714–1768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
van den Berg B, Walgaard C, Drenthen J,
Fokke C, Jacobs BC and van Doorn PA: Guillain-Barre syndrome:
Pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol.
10:469–482. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Smigiel KS, Srivastava S, Stolley JM and
Campbell DJ: Regulatory T-cell homeostasis: Steady-state
maintenance and modulation during inflammation. Immunol Rev.
259:40–59. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kumar P, Bhattacharya P and Prabhakar BS:
A comprehensive review on the role of co-signaling receptors and
Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun.
95:77–99. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fujii H, Josse J, Tanioka M, Miyachi Y,
Husson F and Ono M: Regulatory T cells in melanoma revisited by a
computational clustering of FOXP3+ T cell subpopulations. J
Immunol. 196:2885–2892. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ormandy LA, Hillemann T, Wedemeyer H,
Manns MP, Greten TF and Korangy F: Increased populations of
regulatory T cells in peripheral blood of patients with
hepatocellular carcinoma. Cancer Res. 65:2457–2464. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tao H, Mimura Y, Aoe K, Kobayashi S,
Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K and Ueoka H:
Prognostic potential of FOXP3 expression in non-small cell lung
cancer cells combined with tumor-infiltrating regulatory T cells.
Lung Cancer. 75:95–101. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Syed Khaja AS, Toor SM, El Salhat H, Faour
I, Ul Haq N, Ali BR and Elkord E: Preferential accumulation of
regulatory T cells with highly immunosuppressive characteristics in
breast tumor microenvironment. Oncotarget. 8:33159–33171.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Takeuchi Y and Nishikawa H: Roles of
regulatory T cells in cancer immunity. Int Immunol. 28:401–409.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J. 356:115–124. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ravaud A, Motzer RJ, Pandha HS, George DJ,
Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, et
al: Adjuvant sunitinib in high-risk renal-cell carcinoma after
nephrectomy. N Engl J Med. 375:2246–2254. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Randrup Hansen C, Grimm D, Bauer J,
Wehland M and Magnusson NE: Effects and side effects of using
sorafenib and sunitinib in the treatment of metastatic renal cell
carcinoma. Int J Mol Sci. 18(pii: E461)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mulherin B, Loconte NK and Holen KD:
Guillain-Barre syndrome after treatment with sunitinib malate?
Oncology (Williston Park). 22:66–67. 2008.PubMed/NCBI
|
|
21
|
Kanaan Z, Kulairi Z, Titianu M, Saha S and
Kumar S: Guillain-barre syndrome following treatment with sunitinib
malate. Case Rep Oncol Med. 2014(712040)2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Aparicio-Gallego G, Blanco M, Figueroa A,
Garcia-Campelo R, Valladares-Ayerbes M, Grande-Pulido E and
Anton-Aparicio L: New insights into molecular mechanisms of
sunitinib-associated side effects. Mol Cancer Ther. 10:2215–2223.
2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fukumoto Y, Kuwahara M, Kawai S, Nakahama
K and Kusunoki S: Acute demyelinating polyneuropathy induced by
nivolumab. J Neurol Neurosurg Psychiatry. 89:435–437.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gu Y, Menzies AM, Long GV, Fernando SL and
Herkes G: Immune mediated neuropathy following checkpoint
immunotherapy. J Clin Neurosci. 45:14–17. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Jacob A, Unnikrishnan DC, Mathew A,
Thyagarajan B and Patel S: A case of fatal Guillain-Barre syndrome
from anti-PD1 monoclonal antibody use. J Cancer Res Clin.
142:1869–1870. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kyriazoglou A, Liontos M, Papadopoulos C,
Bilali A, Kostouros E, Pagoni S, Doumas K, Dimopoulos MA and Bamias
A: Guillain-barre syndrome related to nivolumab: Case report of a
patient with urothelial cancer and review of the literature. Clin
Genitourin Cancer. 17:e360–e364. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nukui T, Nakayama Y, Yamamoto M, Taguchi
Y, Dougu N, Konishi H, Hayashi T and Nakatsuji Y: Nivolumab-induced
acute demyelinating polyradiculoneuropathy mimicking Guillain-Barre
syndrome. J Neurol Sci. 390:115–116. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Schneiderbauer R, Schneiderbauer M, Wick
W, Enk AH, Haenssle HA and Hassel JC: PD-1 antibody-induced
guillain-barre syndrome in a patient with metastatic melanoma. Acta
Derm Venereol. 97:395–396. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Supakornnumporn S and Katirji B:
Guillain-barre syndrome triggered by immune checkpoint inhibitors:
A case report and literature review. J Clin Neuromuscul. 19:80–83.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Thapa B, Khalid S, Vakili R, Ui J and
Misbah S: Nivolumab-associated Guillain-barre syndrome in a patient
with non-small-cell lung cancer. Am J Ther. 25:e761–e763.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
de Maleissye MF, Nicolas G and Saiag P:
Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl
J Med. 375:296–297. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Manam R, Martin JL, Gross JA, Chaudhary D,
Chowdhary S, Espinosa PS and Santos ES: Case reports of
pembrolizumab-induced acute inflammatory demyelinating
polyneuropathy. Cureus. 10(e3371)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ong S, Chapman J, Young G and Mansy T:
Guillain-Barre-like syndrome during pembrolizumab treatment. Muscle
Nerve. 58:e8–e10. 2018.PubMed/NCBI View Article : Google Scholar
|
